)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Oncoinvent
Oncoinvent (ONCIN) investor relations material
Oncoinvent Investor update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor update summary28 Oct, 2026
Operational progress
Enrolled 71 patients by end-Q3, ~2/3 of the target, including 44 YTD and 16 in Q3; recruitment held near Q2 pace despite a two-week maintenance closure.
11 active recruiting sites, with five added YTD across Italy, the UK, Spain and Belgium; protocol amendments lowered inclusion thresholds and supported recruitment.
Q4 recruitment tracked at a similar pace, with 2026 priorities on track.
Scientific activity and leadership
Normal-tissue dosimetry results published in the Journal of Nuclear Medicine; three abstracts presented at ESMO and EANM.
Dr Zuzana Jirakova Trnkova appointed CMO, bringing 20+ years of drug-development experience, including Phase III and alpha-emitter radiopharmaceuticals.
Financing and runway
September private placement and retail offering raised NOK 148.5m gross; cash was NOK 200m at end-September, extending runway into H2 2027 and beyond the April 2027 interim readout.
Spend reached NOK 110m by end-Q3; monthly burn was in the low teens and stable versus the start of the year despite increased recruitment.
Proceeds support Phase II completion, FDA and EMA alignment, Phase III planning, manufacturing scale-up and early trial-start activities.
A second manufacturing location through a CDMO, likely in the US, is planned to de-risk supply; Phase III funding may involve equity or strategic/pharma partners.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Oncoinvent
- Accelerated clinical progress and financing position RadspherinⓇ for pivotal trials and major market entry.ONCIN
Company presentation - Phase II trial recruitment accelerates, cash runway into 2027, but new funding needed soon.ONCINH1 2026
- RadspherinⓇ delivers promising efficacy and safety for peritoneal metastases with blockbuster potential.ONCINInvestor presentation
- RadspherinⓇ demonstrates promising efficacy and safety for peritoneal metastases in major cancers.ONCINInvestor presentation
- Phase 2 recruitment and NOK 130 million in cash support Radspherin development into 2027.ONCINInvestor update
- RadspherinⓇ shows promise in reducing peritoneal cancer recurrence with strong safety data.ONCIN7th Targeted Radiopharmaceuticals Summit Europe presentation
- RadspherinⓇ demonstrates strong efficacy and safety for peritoneal metastases in key cancers.ONCINDNB Carnegie Nordic Healthcare Conference presentation
- Merger with Oncoinvent ASA and rights issue mark a new phase after clinical program closures.ONCINQ2 2025
- BGBC016 study discontinued after weak efficacy; strategic review and cost control underway.ONCINQ4 2024
Next Oncoinvent earnings date
H2 202626 Feb, 2027
Oncoinvent
Next Oncoinvent earnings date
H2 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, focused on developing innovative therapies for aggressive diseases such as cancer and severe respiratory infections. The company specializes in AXL kinase inhibitors, with its lead product, Bemcentinib, currently undergoing clinical trials for non-small cell lung cancer (NSCLC) and severe respiratory conditions. Another key asset, Tilvestamab, is a monoclonal antibody targeting AXL, being investigated for the treatment of ovarian cancer. BerGenBio is leveraging its expertise in AXL biology to create treatments that can potentially improve outcomes in diseases characterized by drug resistance and immune evasion. The company's strategy includes partnerships with clinical sites and biopharma firms to advance its drug pipeline. The company is headquartered in Bergen, Norway, and its shares are traded on the Oslo Stock Exchange.